Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Payables: 2011-2025

Historic Payables for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to $2.7 million.

  • Capricor Therapeutics' Payables fell 58.36% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.1 million, marking a year-over-year decrease of 36.23%. This contributed to the annual value of $3.3 million for FY2024, which is 47.46% down from last year.
  • Latest data reveals that Capricor Therapeutics reported Payables of $2.7 million as of Q3 2025, which was down 43.49% from $4.8 million recorded in Q2 2025.
  • Capricor Therapeutics' Payables' 5-year high stood at $6.8 million during Q3 2023, with a 5-year trough of $2.7 million in Q3 2025.
  • Moreover, its 3-year median value for Payables was $5.4 million (2023), whereas its average is $5.3 million.
  • In the last 5 years, Capricor Therapeutics' Payables surged by 189.44% in 2021 and then plummeted by 58.36% in 2025.
  • Capricor Therapeutics' Payables (Quarterly) stood at $3.1 million in 2021, then surged by 55.14% to $4.8 million in 2022, then increased by 29.28% to $6.3 million in 2023, then crashed by 47.46% to $3.3 million in 2024, then slumped by 58.36% to $2.7 million in 2025.
  • Its Payables stands at $2.7 million for Q3 2025, versus $4.8 million for Q2 2025 and $5.3 million for Q1 2025.